
mTOR, S6 and AKT expression in relation to proliferation and ... - PubMed
Background: The mammalian target of rapamycin (mTOR) controls cell growth through protein synthesis regulation. It can be activated by protein kinase B (AKT) or through ribosomal S6 kinase (S6K1).
S6K1-mediated phosphorylation of PDK1 impairs AKT kinase
Mar 22, 2022 · Here we report that ribosomal protein S6 kinase beta 1 (S6K1), a member of AGC kinases and downstream target of mechanistic target of rapamycin complex 1 (mTORC1), directly phosphorylates...
Phospho-S6 ribosomal protein: a potential new predictive ... - Nature
Dec 21, 2007 · The serine/threonine kinase, mammalian target of rapamycin (mTOR), is a protein kinase of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway thought to have a key role in...
The mTORC1 effectors S6K1 and 4E-BP play different roles in
Nov 10, 2014 · The two best-characterized downstream signalling molecules of mTORC1 are ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E (eIF4E)-binding protein (4E-BP) 19 ...
Overexpressed p-S6 associates with lymph node metastasis and …
May 20, 2022 · Ribosomal protein S6 (S6), a downstream effect media of the AKT/mTOR pathway, not only is a part of 40S small subunit of eukaryotic ribosome, but also involves in protein synthesis and cell proliferation during cancer development.
May 1, 2018 · Protein S6K1 (S6) is downstream of mammalian target of rapamycin (mTOR), whereas protein kinase B (AKT) is upstream of mTOR. Therefore, to evaluate the pharmacodynamic effects of the mTOR inhibitor RAD001 (everolimus) in patients with myelodysplastic syndrome, S6 and AKT phosphorylation (pS6, pAKT) were measured by peripheral blood flow cytometry.
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling ...
Oct 15, 2003 · Tsc2–/–TP53–/– cells, as well as tumors from Tsc2+/– mice, display an mTOR-activation signature with constitutive activation of S6K, which is reverted by treatment with rapamycin. Rapamycin also reverts a growth advantage of Tsc2–/–TP53–/– cells.
Activation of mTOR/S6K But Not MAPK Pathways Might Be
The expression levels of Ki-67, p53, phosphorylated MAPK (pMAPK), and protein S6 (pS6; downstream molecule of PI3K/Akt/mammalian target of rapamycin/S6 kinase pathway) were determined immunohistochemically. pS6 positivity, but not pMAPK positivity, was significantly associated with the high Ki-67 expression subset.
Ribosomal S6 Kinase and AKT Phosphorylation as …
Apr 1, 2014 · This report focuses on evaluation of the phosphorylation of protein S6K1 and AKT (pS6, pAKT) in peripheral blood and bone marrow samples from patients receiving treatment with RAD001, to evaluate these biomarkers as potential indicators of RAD001 molecular pharmacodynamic effect.
Balancing Akt with S6K: implications for both metabolic ... - PubMed
Nov 8, 2004 · Proper regulation of the phosphoinositide 3-kinase-Akt pathway is critical for the prevention of both insulin resistance and tumorigenesis.